Literature DB >> 17452818

Review of the clinicopathologic features of fibrolamellar carcinoma.

Michael Torbenson1.   

Abstract

Since its first description 50 years ago, fibrolamellar carcinomas (FLCs) have been recognized as a unique type of primary liver cancer. FLCs occur principally in children and young adults and are not associated with chronic liver disease. Their etiology is unknown. The tumor is made up of large polygonal cells containing abundant eosinophilic cytoplasm, large vesiculated nuclei, and large nucleoli, with tumor cells that are embedded in lamellar bands of fibrosis. Although rare, the most common variant of FLC shows areas of glandular type differentiation with mucin production. The uniqueness of FLC extends to their molecular findings, as they show no evidence for involvement by many of the major pathways and genes that are dysregulated in typical hepatocellular carcinoma, including alpha-fetoprotein, TP53 mutations, and beta catenin mutations. FLCs are not indolent tumors, but have an overall better prognosis than hepatocellular carcinomas of the usual sort because of the younger age at presentation and lack of cirrhosis. The most important prognostic feature is resectability. Although their morphologic appearance on routine stains is well defined, their etiology is still unknown and much of their molecular biology remains poorly described and awaits future investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17452818     DOI: 10.1097/PAP.0b013e3180504913

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  33 in total

1.  Fibrolamellar hepatocellular carcinoma with cardiac spread causing severe inferior vena cava obstruction in a 9-year-old child.

Authors:  Jarrod D Knudson; Jason F Goldberg; Nancy A Ayres
Journal:  Pediatr Cardiol       Date:  2012-03-25       Impact factor: 1.655

Review 2.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

3.  Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan
Journal:  Oncology       Date:  2013-09-19       Impact factor: 2.935

4.  CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.

Authors:  Lars H Engelholm; Anjum Riaz; Denise Serra; Frederik Dagnæs-Hansen; Jens V Johansen; Eric Santoni-Rugiu; Steen H Hansen; Francesco Niola; Morten Frödin
Journal:  Gastroenterology       Date:  2017-09-18       Impact factor: 22.682

5.  Fibrolamellar hepatocellular carcinoma: a case report with distinct radiological features.

Authors:  Ioannis Terzis; Afrodite Haritanti; Ipoliti Economou
Journal:  J Gastrointest Cancer       Date:  2010-03

6.  Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas.

Authors:  Perumal Vivekanandan; Hubert Daniel; Matthew M Yeh; Michael Torbenson
Journal:  Mod Pathol       Date:  2010-03-12       Impact factor: 7.842

7.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

8.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

9.  Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.

Authors:  Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun
Journal:  J Gastrointest Surg       Date:  2016-07-25       Impact factor: 3.452

Review 10.  [Tumor grading of the hepatobiliary system].

Authors:  H Jütte; A Tannapfel
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.